Stockreport

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience, Inc.  (ANRO) 
PDF – Patent supports Alto’s precision approach to improve patient selection – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a cli [Read more]